Laurie H. Glimcher, MD
President and Chief Executive Officer
Laurie H. Glimcher, MD, became the president and chief executive officer of the Institute in October 2016
and also serves as chief executive officer of Dana-Farber/Partners CancerCare, director of Dana-Farber/Harvard Cancer Center, and a trustee of Dana-Farber/Children's Hospital Cancer Care. Dr. Glimcher is the Richard and Susan Smith Professor of Medicine
and a professor of Microbiology and Immunobiology at Harvard Medical School. She received a bachelor's degree, magna cum laude
, from Radcliffe College and a medical degree, cum laude
, from Harvard Medical School.
Immediately prior to assuming the presidency of the Institute, Dr. Glimcher served as the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medical College in New York City, and Provost for Medical Affairs of Cornell University.
From 1991-2011, Dr. Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, where she was director of the Division of Biological Sciences, and Professor of Medicine at Harvard Medical School, where she headed
one of the top immunology programs in the world.
Dr. Glimcher is the recipient of many awards and honors. Most recently, she received the Indiana University School of Medicine's Steven C. Beering Award for outstanding research contributions to advancement of biomedical or clinical science; the L'Oréal-UNESCO Award for Women in Science; the 2017 George M. Kober Medal; and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges (AAMC).
Dr. Glimcher has made numerous discoveries that have advanced treatments for many diseases and chronic conditions, including cancer, asthma, and osteoporosis. She is widely considered to be the international authority on the development and activation of lymphocytes in the immune system.
As an immunologist, her primary research interests are elucidating the molecular pathways that regulate the immune system, critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious
and malignant diseases. She is a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine and a Member of the National Academy of Sciences. She sits on the Board of Trustees of the Parker Institute for Cancer
Immunotherapy and on the Corporate Board of Directors of the Waters Corporation and GlaxoSmithKline plc.
Learn more about Laurie Glimcher, MD
Dorothy E. Puhy
Executive Vice President and Chief Operating Officer
Dorothy E. Puhy became the Institute's chief operating officer in 2012. She previously served as chief financial
officer and director for Fiscal Services since 1994, and executive vice president since 2004. Ms. Puhy is chief administrative officer of Dana-Farber/Partners CancerCare and treasurer of HealthCare Dimensions, Inc.
Prior to joining Dana-Farber, she was chief financial officer at New England Medical Center in Boston and a senior manager at Ernst and Whinney. Ms. Puhy received her bachelor's degree from the University of Pennsylvania and her business degree from its
Scott A. Armstrong, MD, PhD
Chair, Department of Pediatric Oncology
Scott A. Armstrong, MD, PhD, is chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute,
and the David G. Nathan Professor of Pediatrics. He also serves as associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Dr. Armstrong was previously director of the Center for Epigenetics Research at Memorial Sloan Kettering
Cancer Center and Professor of Pediatrics at the Weill Cornell Medical College. He earned his medical degree and PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency
Program (BCRP) at Boston Medical Center and Boston Children’s Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
The major focus of Dr. Armstrong’s career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and
the relationship between leukemia and normal hematopoietic stem cells. Dr. Armstrong continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin-based mechanisms, and he is actively involved
in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.
Richard S. Boskey
Senior Vice President and General Counsel
Richard S. Boskey joined the Institute in 1999. He serves as assistant secretary of Dana-Farber Cancer Institute and Dana-Farber/Partners CancerCare, and secretary of the Dana-Farber Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care. Previously,
he served in various positions at Partners HealthCare and Massachusetts General Hospital, including deputy general counsel, and was an associate at the law firm Hill & Barlow. Mr. Boskey received his bachelor's degree from Brown University and his
master's and law degrees from the University of Virginia.
Craig A. Bunnell, MD, MPH, MBA
Chief Medical Officer
Craig A. Bunnell, MD, MPH, MBA, became the chief medical officer and medical director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College
after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts
Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as chief medical resident. Dr. Bunnell is a medical oncologist involved in research
and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
George D. Demetri, MD
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
, advances institutional efforts in the discovery and development of novel anticancer therapies based on experience gained from his leadership in several drug development efforts, including
imatinib (Gleevec) in patients with the sarcoma known as gastrointestinal stromal tumor (GIST), one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor.
Dr. Demetri's role at Dana-Farber is also complemented by serving as the co-director of the Ludwig Center at Harvard along with Joan Brugge, PhD, of Harvard Medical School, comprising more than 30 investigative teams collaborating across Harvard-affiliated
institutions to understand, overcome and prevent resistance of cancers to therapeutic interventions. Dr. Demetri trained at Harvard College and Stanford University School of Medicine, followed by internal medicine residency and chief residency at
the University of Washington Hospitals in Seattle. He also co-directs the Harvard Medical School Global Education course on Cancer Biology and Therapeutics.
Lisa R. Diller, MD
Chief Medical Officer, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Lisa R. Diller, MD, chief medical officer at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is also the clinical director of Pediatric Oncology, and the medical director of the David B.
Perini, Jr. Quality of Life Clinic. Her research focuses on the late effects of treatment of childhood cancer and genetic cancer predispositions in childhood; her clinical work focuses on pediatric solid tumors. Dr. Diller received her bachelor’s
degree from Harvard University and earned her Doctor of Medicine from the University of California at San Diego.
Gerard M. Doherty, MD
Chair of Surgery
A graduate of College of the Holy Cross and Yale School of Medicine,
Gerard M. Doherty, MD, completed residency training at UCSF, including a fellowship at the National Cancer Institute. He joined Washington University School of Medicine in 1993, and became professor of
Surgery in 2001. In 2002 he was named head of General Surgery and Thompson Professor of Surgery at the University of Michigan, where he also served as General Surgery Program director and vice chair of the Department of Surgery. From 2012 to 2016,
Dr. Doherty was Utley Professor and Chair of Surgery at Boston University and surgeon-in-chief at Boston Medical Center, before becoming professor of Surgery at Harvard Medical School, and surgeon-in-chief at Brigham and Women’s Hospital.
Dr. Doherty has focused on surgical diseases of the thyroid, parathyroid, endocrine, pancreas, and adrenal glands, as well as the surgical management of MEN syndromes. He has devoted substantial effort to medical student and resident education policy.
His bibliography includes over 300 peer-reviewed articles, reviews, and book chapters, and several edited books.
He currently serves as president-elect of the International Association of Endocrine Surgeons, past-president of the American Association of Endocrine Surgeons, member of the Surgical Oncology Board of the American Board of Surgery (ABS), editor-in-chief
of VideoEndocrinology, and reviews editor of JAMA Surgery.
Benjamin Ebert, MD, PhD
Chair of Medical Oncology
Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber Cancer Institute, is professor of Medicine at Harvard Medical School, an institute member of the Broad Institute, and leader of the Leukemia
Program for the Dana-Farber/Harvard Cancer Center.
His research focuses on the genetics, biology, and therapy of myeloid malignancies. This work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of
lenalidomide and related molecules that induce degradation of specific proteins.
Dr. Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an MD from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship
in hematology/oncology at Dana-Farber.
David A. Feinberg
Vice President, Chief Marketing Officer
David A. Feinberg brings over 30 years of consumer and healthcare marketing experience to his current position of Vice President, Chief Marketing Officer. Prior to joining Dana-Farber, Mr. Feinberg served as Chief Marketing Officer for NewYork-Presbyterian
Hospital, where he was responsible for marketing, advertising, physician referral, Internet, and visitor information strategies. Other previous experience includes leading the healthcare practice of The Seiden Group, an advertising and marketing firm,
as well as positions at Ciba-Geigy (now Novartis), Procter & Gamble, and Clairol. He received a bachelor of science degree in economics from the Wharton School of the University of Pennsylvania and a master’s degree in management and marketing from
Northwestern University’s Kellogg School of Management.
Anne Gross, PhD, RN, NEA-BC, FAAN
Senior Vice President, Patient Care Services and Chief Nursing Officer
Anne Gross, PhD, RN, NEA-BC, FAAN, became Dana-Farber’s senior vice president for patient care services and chief nursing officer in 2016. She joined Dana-Farber in 2002 and since 2004 served as vice
president, Adult Nursing and Clinical Services. Dr. Gross is a Fellow of the American Academy of Nursing and currently serves as co-chair elect of the Academy’s Fellows Selection Committee. Prior to joining Dana-Farber, she was a clinical nurse and
leader, most recently at Cambridge Health Alliance. She received her bachelor's degree in nursing from St. Louis University, her master’s degree in nursing from Boston College, and her doctoral degree from the University of Massachusetts.
Daphne Haas-Kogan, MD
Professor and Chair, Department of Radiation Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Boston Children’s Hospital
Daphne Haas-Kogan, MD, received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology
at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). Dr. Haas-Kogan spent 18 years as a radiation oncologist, researcher, and academic leader in the UCSF HDFCCC system before becoming chair of the Department of Radiation Oncology
at Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.
William C. Hahn, MD, PhD
Chief Research Strategy Officer (CRSO)
Chair, Executive Committee for Research (ECR)
William C. Hahn, MD, PhD, is the chief research strategy officer and chair of the Executive Committee for Research at Dana-Farber, where he has been engaged in clinical care and research since 1996. He
is chief of the Division of Molecular and Cellular Oncology in the Department of Medical Oncology and an Institute Member of the Broad Institute of MIT and Harvard. He received his AB in Biochemical Science, PhD in Immunology and MD all from Harvard
University and completed his clinical training at Massachusetts General Hospital and Dana-Farber Cancer Institute. His research focuses on understanding how mutations cooperate in cancer initiation and progression to develop rational combination therapies.
Senior Vice President for Human Resources
Deborah Hicks joined Dana-Farber as the senior vice president for Human Resources in 2011. Prior to joining
Dana-Farber, Ms. Hicks served as the associate dean and chief human resources officer at Harvard Medical School.
She joined Harvard Medical School in January 2009. Previously, Ms. Hicks was the vice president of Human Resources at Harvard Pilgrim Health Care (HPHC), joining HPHC in 1988 and becoming vice president of Human Resources and part of the leadership team
in 1999, where she was instrumental in supporting the organization during the turnaround of HPHC from receivership to profitability.
She currently serves as chair of the Board of the New England Human Resources Association, holds a master's degree in Counseling Psychology/Organizational Management from Antioch University, and a bachelor's degree from the University of Massachusetts
Joseph Jacobson, MD
Joseph Jacobson, MD
Chief Quality Officer
, joined Dana-Farber Cancer Institute in 2011 as the Institute's first chief quality officer, overseeing clinical quality programs across Dana-Farber and its affiliates, and representing
Dana-Farber in regional and national quality improvement efforts. He focuses on clinical process measurement and improvement, efficiency and effectiveness of care, and quality leadership development. He is also a member of and practicing physician in
our Thoracic Oncology Program.
Before joining Dana-Farber, Dr. Jacobson served as the chairman of medicine at North Shore Medical Center. As part of the Partners Healthcare system, he co-developed and currently co-directs the Partners Clinical Process Improvement Leadership Program.
He has an extensive track record in quality measurement and quality improvement, serving as a founding member of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative, as co-developer of the ASCO/ONS Chemotherapy Safety
Standards and as recent past Chair of the ASCO Quality of Care Committee.
Bruce E. Johnson, MD
Bruce E. Johnson, MD
Chief Clinical Research Officer
, became Dana-Farber’s chief clinical research officer in 2013. He previously was director of the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center. He
is also professor of Medicine at Harvard Medical School and an American Society of Clinical Oncology translational research professor. Dr. Johnson is serving as the interim director of the Center for Cancer Precision Medicine (CCPM).
Dr. Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute. In 1992, he became head of the Lung Cancer
Biology Section, Medicine Branch, at the NCI, until 1998, when he joined Dana-Farber. Dr. Johnson is currently serving as president of the American Society of Clinical Oncology.
Dr. Johnson directs the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic
Jason M. Johnson, PhD
Chief Health Information Officer
Jason M. Johnson, PhD, joined the Institute in April 2016 and serves as Chief Health Information Officer. Prior to joining Dana-Farber, Dr. Johnson was executive vice president and head of R&D at PatientsLikeMe, a patient-focused research company in Cambridge,
MA. He came to that position after serving in various leadership roles in scientific informatics, bioinformatics, and genomics at Merck for many years. Dr. Johnson holds AB and BS degrees from Stanford University, a master’s degree from the University
of Cambridge (UK), and a PhD in Biophysics from Harvard University.
Elizabeth A. Liebow
Senior Vice President of Business Development, Clinical Planning, and Community Site Operations
Elizabeth A. Liebow, who joined Dana-Farber in 2004, is responsible for planning and business development
for clinical services at Dana-Farber, as well as operational oversight of Dana-Farber's satellite locations and physician practices. Most notably, she directed the development of Dana-Farber's four satellite clinics and acquisition of eight physician
practice sites, facilitated clinical operations planning for the Yawkey Center for Cancer Care, and oversaw strategic clinical growth planning efforts.
Ms. Liebow is currently focused on developing new partnerships with additional community sites and integrated delivery systems, continuing clinical growth on Dana-Farber's main campus, expanding care beyond New England, and improving efficiency and cost
effectiveness in the community-based sites.
Ms. Liebow holds a Master of Science in Health Policy and Management from the Harvard School of Public Health and a BA in Economics from Brandeis University.
Senior Vice President for Institute Operations
Maria Megdal joined Dana-Farber Cancer Institute as the vice president for facilities management and real
estate in 2008 and was named senior vice president for institute operations in 2012.
Before joining Dana-Farber, Ms. Megdal served as vice president for corporate real estate services at Saint Vincent Catholic Medical Centers of New York. Prior to Saint Vincent's, Ms. Megdal held various management roles at Memorial Sloan-Kettering Cancer
Center after completing her administrative residency there.
Ms. Megdal holds a masters in health administration from Cornell University and a bachelors degree in physical anthropology from Rutgers University. She is a longtime member of several alumni boards at Cornell where she serves as adjunct lecturer on facilities
Senior Vice President for Research, Dana-Farber Cancer Institute
Associate Director for Administration, Dana-Farber/Harvard Cancer Center
Drew Memmott joined Dana-Farber in 2014 as the senior vice president for research administration and the associate director for administration for the Dana-Farber/Harvard Cancer Center. Prior to joining Dana-Farber, Mr. Memmott served as the associate
director for administration for the Mayo Clinic Cancer Center and as a director for research administration at Columbia University Medical Center. Mr. Memmott received his bachelor's degree from the University of Utah and graduate degrees from the
University of Washington and Columbia University.
Lee M. Nadler, MD
Senior Vice President, Experimental Medicine
Lee M. Nadler, MD, received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor
immunology, he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department
of Adult Oncology. Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan-Mass Challenge Chair at Dana-Farber.
Susan S. Paresky
Senior Vice President for Development and the Jimmy Fund
Susan S. Paresky joined the Institute in 1997. Prior to this, she was associate dean for Development at the Harvard School of Public Health, where she executed the school's fundraising program as part of Harvard University's $2 billion campaign. She has
also held senior positions at Brandeis University and Wheaton College. Ms. Paresky received her business degree from Simmons School of Management and her bachelor's degree from Wheaton College, where she served as a trustee for many years and received
an honorary degree in 2011.
Michael L. Reney
Senior Vice President for Finance and Chief Financial Officer
Michael Reney joined Dana-Farber in 2015. He previously served as chief financial officer at Brigham and
Women’s Hospital (BWH). Mr. Reney began his career as a senior auditor at Deloitte & Touche LLP, after which he joined BWH. His extensive experience includes serving as assistant controller at Massachusetts General Hospital, followed by several positions
within Partners Healthcare. In 2000, he returned to BWH as controller and executive director of Finance, and was named senior vice president for finance and chief financial officer for Brigham and Women's Health Care (BWHC) in 2008.
Mr. Reney holds a bachelor’s degree in accounting from Bentley College and an MBA from the University of Massachusetts, Boston. He is a member of the Healthcare Financial Management Association, as well as the Healthcare Roundtable for CFOs. Mr. Reney
serves on the boards of the Fenway Community Health Center, Medical Academic and Scientific Community Organization (MASCO), Brigham Research Foundation, and Longwood Medical Energy Corporation.
Barrett J. Rollins, MD, PhD
Barrett J. Rollins, MD, PhD
Chief Scientific Officer
, received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel
Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins is currently Professor of Medicine at Harvard Medical School.
Stephen E. Sallan, MD
Chief of Staff Emeritus
Stephen E. Sallan, MD, joined the institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medical
Staff Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick
Family Senior Investigator in 2002.
Steven R. Singer
Senior Vice President for Communications
Steven R. Singer joined the Institute in 1997. He previously served as director of Communications and Public Affairs and adjunct lecturer at Harvard University's John F. Kennedy School of Government. He has worked as a press secretary in the U.S. House
of Representatives, and is past chair of the National Cancer Institute's Public Affairs Network. Mr. Singer received his bachelor's degree from Colby College and a master's degree in public administration from Harvard University's Kennedy School.
Robert J. Soiffer, MD
Robert J. Soiffer, MD
Chair, Executive Committee for Clinical Programs (ECCP)
, is professor of Medicine at Harvard Medical School and institute physician at Dana-Farber. He is chief of the Division of Hematologic Malignancies, vice-chairman of Medical Oncology,
and co-director of the Bone Marrow Transplant Service at Dana-Farber. He serves on the Executive Committee for Clinical Practice, the Executive Committee for Clinical Research, and the Executive Patient Safety Oversight Group at Dana-Farber.
Dr. Soiffer is a former president of the American Society for Blood and Marrow Transplantation. He served on the advisory board for the Center for International Blood and Marrow Transplant Research. He is a member of the executive steering committees
for the Blood and Marrow Transplant Clinical Trials Network; serves on the board of directors for the National Marrow Donor Program Be the Match Registry; and serves on the board of the Massachusetts chapter of the Leukemia & Lymphoma Society.
Senior Vice President and Chief Innovation Officer
Lesley Solomon became Dana-Farber’s senior vice president and chief innovation officer in 2017. She has served as the founding executive director of Brigham and Women’s Hospital's Innovation Hub, and as director of strategy and innovation in the Brigham
Ms. Solomon has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA
from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of Harvard and MIT, which brings together experts across disciplines to unlock the biology
of food allergy and change the field to develop new treatments and more.
Richard Stone, MD
Richard Stone, MD
Chief of Staff
Professor of Medicine, Harvard Medical School
, is director of Dana-Farber's Adult Acute Leukemia Program. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including
acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (MDS), a bone marrow failure state that may convert to leukemia.
In addition to his work at Dana-Farber, Dr. Stone serves as chair of the Medical Oncology Board of the American Board of Internal Medicine, chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and chairman of the
Leukemia Core Committee for the Alliance for clinical Trials in Oncology.
Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women's Hospital and his hematology-oncology fellowship at Dana-Farber.
Mary-Ellen Taplin, MD
Chair, Executive Committee for Clinical Research (ECCR)
Mary-Ellen Taplin, MD, joined the Institute in 2003. She serves as director of clinical research for the Lank Center for Genitourinary Oncology at Dana-Farber /Brigham and Women’s Cancer Center. She
is also associate professor of Medicine at Harvard Medical School. She is an investigator on many projects, including the Prostate Cancer Clinical Trial Consortium, Dana-Farber SPORE grant, Stand Up 2 Cancer, and several Prostate Cancer Foundation
Challenge Grants. Dr. Taplin has been dedicated to clinical and translational investigations that focus on novel approaches to treating localized high risk prostate cancer and secondary hormone therapy for metastatic castration-resistant prostate
cancer. She has described molecular and physiologic alterations in the androgen receptor pathway in the context of prostate cancer resistance. Dr. Taplin is dedicated to patient care and clinical investigation in genitourinary oncology.
James Tulsky, MD
Chair, Department of Psychosocial Oncology and Palliative Care
James Tulsky, MD, received his AB from Cornell University, his MD from the University of Illinois College of Medicine at Chicago, and completed internal medicine training at the University of California,
San Francisco (UCSF). He continued at UCSF as chief medical resident and subsequently as a Robert Wood Johnson Clinical Scholar. Dr. Tulsky was on the faculty of Duke University from 1993-2015, lastly as professor of Medicine and Nursing and chief,
Duke Palliative Care. He joined Dana-Farber Cancer Institute in 2015 to be Chair, Department of Psychosocial Oncology and Palliative Care. Dr. Tulsky has a longstanding research interest in clinician-patient communication and quality of life in serious
Annick D. Van den Abbeele, MD
Chief, Department of Imaging
Annick Van den Abbeele, MD, received her BA and MD from the Université Catholique de Louvain in Belgium. Following a residency in Pediatrics at the Université Catholique de Louvain and a Neonatology
fellowship at Vanderbilt University Medical Center in Nashville, TN, she completed a residency in Nuclear Medicine and a fellowship in Radiology at Brigham and Women's Hospital, Boston, MA and Harvard Medical School, followed by seven years in basic
sciences research. In 1994, Dr. Van den Abbeele assumed the position of Director of Nuclear Medicine at the Dana-Farber Cancer Institute, and in 2004 became the clinical director of Radiology. In 2006, she was promoted to chief of the Department of
Imaging. She has been a faculty member at Harvard Medical School since 1987.
David A. Williams, MD
David A. Williams, MD
President, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
, is chief of Hematology/Oncology and director of Clinical and Translational Research at Boston Children’s Hospital and associate chairman, Department of Pediatric Oncology at Dana-Farber
Cancer Institute. He is director of the Pediatric Hematology/Oncology Fellowship Training Program at Dana-Farber/Boston Children’s.
Dr. Williams’ laboratory has been continuously NIH-funded since 1986. He has served on multiple NIH Study Sections, including currently on the Loan Repayment Study Section for Pediatrics; he served for five years on the NCI Parent Committee for Comprehensive
Cancer Centers. Dr. Williams served on both the Recombinant DNA Advisory Committee (RAC) and the NIH Gene Therapy Safety Advisory Board. He is a past President of the American Society of Hematology. He has trained over 45 fellows and post-doctoral
fellows and numerous residents and medical students in his laboratory, the majority of whom are still in academic medicine.
Dr. Williams is a member of the National Academy of Sciences. He has published over 250 peer-reviewed manuscripts, over 100 invited reviews, and multiple textbook chapters. He is actively involved in gene therapy trials for blood, immunodeficiency, and
neurological genetic diseases.
Eric P. Winer, MD
Eric P. Winer, MD
Senior Vice President for Medical Affairs and Chief Clinical Strategy Officer
, is Dana-Farber's senior vice president for medical affairs and chief clinical strategy officer. He is chief of the Division of Women's Cancers and director of the Breast Oncology Center at Dana-Farber/Brigham and Women's Cancer Center, and one of the
leaders of the Institute's Susan F. Smith Center for Women's Cancers. In addition, he is director of the Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer and Professor of Medicine at Harvard Medical School.
Dr. Winer's BA and MD degrees are from Yale University. He was a physician and associate professor of medicine at Duke University School of Medicine before coming to Dana-Farber in 1997.